NGNE vs TSHA
NGNE: Neurogene is a clinical-stage gene therapy company developing a proprietary transgene regulation platform to treat rare, severe neurological disorders like Rett syndrome. TSHA: Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for rare, monogenic central nervous system disorders.
Side-by-side fundamentals
| Metric | NGNE | TSHA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $26.50 | $4.43 | |
| Market cap | $530M | $1.4B | |
| Net margin FY2025, SEC XBRL | n/a | -1115.3% | |
| Operating margin FY2025, SEC XBRL | n/a | -1130.6% | |
| ROE FY2025, SEC XBRL | -34.1% | -44.1% | NGNE higher |
| ROA FY2025, SEC XBRL | -31.3% | -31.7% | NGNE higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.23 | NGNE lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +3.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +57.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.79 | 1.29 | |
| 1-year return as of 2026-10-08 close | +2.6% | -12.5% | NGNE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.